Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tripartite motif-containing protein 61 (TRIM61) is a member of the TRIM family of proteins, characterized by an N-terminal tripartite motif featuring a RING-type zinc finger, one or two B-box domains, and a coiled-coil region[1][7]. TRIM61 is predicted to function as an E3 ubiquitin-protein ligase, participating in protein ubiquitination and regulation of gene expression, particularly in the context of innate immune responses[2][6][7]. It is encoded by the TRIM61 gene (also known as RNF35) and shares structural features common to the TRIM protein family, which is involved in various cellular processes including transcriptional regulation and antiviral defense[1][2][7]. Genetic associations have linked TRIM61 with Bardet-Biedl syndrome 11 and Leber Plus disease, though there is limited evidence for direct disease causation[2]. Currently, there are no drugs known to specifically target TRIM61, nor is it established as a biomarker or drug safety risk.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tripartite motif-containing protein 61 (TRIM61).